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Background: Bioprostheses preserved with glutaraldehyde, both porcine
and pericardial, have been available as second-generation prostheses for
valve replacement surgery. The performance with regard to structural
valve deterioration with the Carpentier-Edwards supra-annular (CE-
SAV) porcine bioprosthesis and the Carpentier-Edwards Perimount (CE-
P) pericardial bioprosthesis (Baxter Healthcare Corp, Edwards Division,
Santa Ana, Calif) was evaluated to determine whether there was a dif-
ference in mitral valve replacement. Methods: The CE-SAV bioprosthesis
was implanted in 1266 overall mitral valve replacements (isolated mitral,
1066; mitral in multiple, 200) and the CE-P bioprosthesis in 429 overall
mitral valve replacements (isolated mitral, 328; mitral in multiple, 101).
The mean age of the CE-SAV population was 64.2 ± 12.2 years and that
of the CE-P population, 60.7 ± 11.7 years (P = .0001). For the study,
structural valve deterioration was diagnosed at reoperation for explan-
tation. Results: The freedom from structural valve deterioration was
evaluated to 10 years, and the freedom rates reported are at 10 years. For
the overall mitral valve replacement groups, the actuarial freedom from
deterioration was significant (P = .0001): CE-P > CE-SAV for 40 years or
younger, 80% versus 60%; 41 to 50 years, 91% versus 61%; 51 to 60
years, 84% versus 69%; 61 to 70 years, 95% versus 75%. The older than
70-year group was 100% versus 92% (no significant difference). The
actual freedom from structural valve deterioration also demonstrated
the same pattern at 10 years: 40 years or younger, CE-P 82% versus CE-
SAV 68%; 41 to 50 years, 92% versus 70%; 51 to 60 years, 90% versus
80%; 61 to 70 years, 97% versus 88%; and older than 70 years, 100%
versus 97%. The independent risk factors of structural valve deteriora-
tion for the overall mitral valve replacement group were age and age
groups and prosthesis type (CE-SAV > CE-P). The prosthesis type either
in isolated replacement or in multiple replacement was not predictive of
structural valve deterioration. The pathology of structural valve deterio-
ration was different: 70% of CE-P failures were due to calcification and
57% of CE-SAV failures were due to combined calcification and leaflet
tear. Conclusion: The actuarial and actual freedom from structural valve
deterioration, diagnosed at reoperation, is greater at 10 years for CE-P
than for CE-SAV bioprostheses. The mode of failure is different, and the
cause remains obscure. Long-term evaluation is recommended, because
the different modes of failure may alter the clinical performance by 15
and 20 years. (J Thorac Cardiovasc Surg 1999;118:297-305)
W. R. Eric Jamieson, MDa
Michel A. Marchand, MDb
Conrad L. Pelletier, MDa
Robert Norton, MDc
Michel Pellerin, MDa
Thomas W. Dubiel, MDd
Michel R. Aupart, MDb
Willem J. Daenen, MDe
Michael P. Holden, MDc
Tirone E. David, MDa
Eke A. Ryba, MDf
William N. Anderson, Jr, PhDf
From Vancouver and Toronto, Canadaa; Tours Cedex, Franceb; Tyne
and Walsgrave Coventry, United Kingdomc; Uppsala, Swedend;
Leuven, Belgiume; and Irvine, Calif.f
Read at the Twenty-fourth Annual Meeting of The Western Thoracic
Surgical Association, Whistler, British Columbia, June 24-27,
1998.
297
STRUCTURAL VALVE DETERIORATION IN MITRAL REPLACEMENT SURGERY: COMPARISON OF
CARPENTIER-EDWARDS SUPRA-ANNULAR PORCINE AND PERIMOUNT PERICARDIAL 
BIOPROSTHESES
Received for publication July 15, 1998; revisions requested Sept 4,
1998; revisions received March 26, 1999; accepted for publica-
tion April 8, 1999.
Address for reprints: W. R. Eric Jamieson, MD, Suite 3100, 910 West
10th Ave, Vancouver, British Columbia, Canada V5Z 4E3.
Copyright © 1999 by Mosby, Inc.
0022-5223/99 $8.00 + 0 12/6/99233
B ioprostheses, porcine and pericardial, have beenused for cardiac valve replacement surgery for
more than 25 years. The literature provides extensive
documentation that structural valve deterioration (SVD)
is the major complication of bioprostheses necessitat-
ing reoperation. SVD occurs less commonly in older
age groups and to a greater degree with mitral prosthe-
ses than aortic prostheses.
The freedom from SVD is not different between first-
and second-generation porcine bioprostheses.1-3 The
first-generation pericardial bioprostheses, Ionescu-
Shiley (Shiley, Inc, Irvine, Calif) and Hancock pericar-
dial prostheses (Medtronic, Inc, Minneapolis, Minn),
were removed from the market in 1987 at the time
of requirement for premarket approval because of
premature structural failure. The second-generation
Carpentier-Edwards Perimount (CE-P) pericardial bio-
prosthesis (Baxter Healthcare Corp, Edwards Division,
Santa Ana, Calif) has now been used for approximate-
ly 15 years. Numerous publications have documented
the freedom from SVD for aortic valve replacements
for both the CE-P and second-generation porcine bio-
prostheses, especially the Carpentier-Edwards Supra-
Annular (SAV) and Hancock II porcine bioprostheses,
but no formal comparison has been undertaken.4-19 The
performance of the CE-P and the second-generation
porcine bioprostheses with regard to SVD for mitral
valve replacements (MVRs) has not been documented.
The purpose of this documentation is to determine
whether the freedom from SVD for the CE-P and CE-
SAV bioprostheses is similar in MVR. The extensive
experience with the CE-SAV bioprosthesis at the
University of British Columbia is compared with the
CE-P mitral prosthesis experience from 7 European
and Canadian centers.12-19 The study compares struc-
tural failure diagnosed only at reoperation explant for
the evaluation. The CE-SAV experience at the
University of British Columbia was used with exclu-
sion of 24 patients in whom the diagnosis was made
without reoperation and 37 patients in whom stent
dehiscence was diagnosed at reoperation. The stent
dehiscence failure mode was controlled by a manufac-
turing process change made in 1986 and 1987 (detail
provided in the “Discussion”).
The CE-SAV porcine bioprosthesis was introduced
by Carpentier and colleagues20 in 1982 with several
considered improvements over the CE-Standard bio-
prosthesis, namely supra-annular configuration to
reduce transvalvular gradients, optimized stent flexibil-
ity to reduce tissue stress, improved tissue preservation
with reduction of glutaraldehyde fixation pressure to 2
mm Hg, and reduction of strut height of the mitral
model so as to minimize protrusion within the ventric-
ular cavity. The CE-P pericardial prosthesis was also
introduced in 1982 but primarily for aortic valve
replacements to facilitate optimum hemodynamics in
smaller aortic sizes. The leaflets of the CE-P prosthesis
are bovine pericardium fixed without pressure in glu-
taraldehyde and produced by computer-aided design
for optimal leaflet-to-stent matching. The leaflets
achieve satisfactory coaptation without stent-post
sutures used with first-generation pericardial prosthe-
ses. Both the CE-SAV and CE-P valves have the same
structural support with an Elgiloy wire stent (Elgiloy
Ltd, Elgin, Ill) to reduce stress on the tissue by provid-
ing flexibility. The tissue of both prostheses is treated
with the surfactant polysorbate 80, an antimineraliza-
tion agent.
Patients and methods
The CE-SAV porcine bioprosthesis was implanted in 1266
overall MVRs (isolated mitral, 1066; mitral in multiple, 200
replacements). The CE-P pericardial bioprosthesis was
implanted in 429 overall MVRs (isolated mitral, 328; mitral in
multiple, 101 replacements). The mean age of the total
patients was 64.2 ± 12.2 years for the CE-SAV population and
60.7 ± 11.7 years for the CE-P population (P = .0001). The
demographics of the patient populations, detailed in Table I,
are generally similar. The 2 patient populations incorporated
coronary artery bypass (32.5% [412] and 14.9% [64], respec-
tively, for CE-SAV and CE-P). This parameter was dissimilar.
The patient populations have been divided into 5 age
groups: 40 years or younger, 41 to 50 years, 51 to 60 years, 61
to 70 years, and older than 70 years. The follow-up was 98.6%
complete for CE-P and 97.8% for CE-SAV. The CE-P docu-
mentation was completed to late 1997 and the CE-SAV eval-
uation was completed in a 6-month closing interval in 1996.
The definition of SVD incorporates all features designated
in the “Guidelines for Reporting Morbidity and Mortality
After Cardiac Valvular Operations,”21 but for this analysis
only SVD diagnosed at explant reoperation was considered
for evaluation. The CE-SAV population, whose bioprostheses
were implanted in the single center, had excluded 24 patients
in whom the diagnosis was made without reoperation and 37
patients with stent dehiscence (in whom the diagnosis was
made at reoperation) controlled by alteration in the manufac-
turing process 12 years ago. The SVD in the CE-P population
diagnosed without reoperation is not known.
SVD was compared between the 2 bioprostheses by assess-
ment of actuarial and actual freedom from SVD by the
specifically stated age groups. The cases at risk are designat-
ed in all figures illustrating freedom from SVD and patient
survival.
The Kaplan-Meier method was used to estimate the actuar-
ial freedom from SVD and patient survival, and the log rank
statistic test was used to compare the survival curves between
the 2 bioprosthesis types for each specific age group. The
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reported P values are 2-sided. The actual freedom from SVD
was determined by an analog of the Kaplan-Meier method,
cumulative incidence, to estimate the risk probabilities.22,23
The Cox regression analysis was used to evaluate the influ-
ence of age, gender, valve size, prosthesis type, and coronary
artery bypass as risk factors of SVD. The influence of age
was determined as both a continuous and a categoric variable.
The variables are reported as odds ratios with the 95% confi-
dence limits (CI) and the designated P values.
Results
The independent risk factors of SVD by multivariate
analysis for the overall MVR group were age and age
groups and prosthesis type (CE-SAV > CE-P) (Table
II). Valve size, gender, and coronary artery bypass were
not independent predictors of SVD. The prosthesis type
either in isolated replacement or multiple replacement
was not predictive of SVD.
The actuarial freedoms from SVD for overall MVRs
are presented in Table III and Figs 1 and 2; for all age
groups, except those older than 70 years, the freedom
was greater for CE-P than for CE-SAV bioprostheses
(P = .0001). For the 61- to 70-year age group, the actu-
arial freedom for CE-SAV valves was 75.2% ± 3.7%
and for CE-P valves, 95.2% ± 2.1% (P = .0001). For
the 51- to 60-year group, the actuarial freedom for CE-
SAV valves was 69.4% ± 4.5% and for CE-P valves,
84.3% ± 5.0% (P = .0424).
The actuarial freedom from SVD for the patients 60
years of age and younger is designated in Fig 2. For
overall MVR, the actuarial freedom was 64.7% ± 3.3%
for CE-SAV valves and 83.9% ± 3.7% for CE-P valves
(P = .0001).
The actual freedom from SVD for overall MVR is
shown in Table IV and Figs 3 and 4 for all age groups.
In Fig 4 the actual freedom from SVD for the patients
60 years of age or younger is designated for CE-P and
CE-SAV bioprostheses.
The pathologic features of the explanted prostheses for
both CE-P and CE-SAV valves are detailed in Table V.
Dystrophic calcification (only) occurred in 70.4% of CE-
P and 16.9% of CE-SAV prostheses, and leaflet tear with-
out calcification in 18.5% and 26.6%, respectively. The
combination of calcification and leaflet tear occurred in
11.1% of CE-P and 56.5% of CE-SAV prostheses.
Patient survival is illustrated in Table VI. The patient
survival in the overall MVRs is differentiated in the 61-
to 70-year age group only for CE-P > CE-SAV (P =
.0001). The patient survival for the 60 or younger age
group does not differentiate between the prostheses for
overall MVRs (no significant difference). The reopera-
tive mortality for CE-SAV valves was 1.3% for MVR
and 11.5% for MVR and mitral in multiple (combined
MVR and mitral in multiple, 2.8%). The reoperative
mortality was not collected for the CE-P prostheses.
Discussion
SVD remains the major valve-related complication
of biologic tissue. This documentation reveals that the
performance of the CE-P pericardial bioprosthesis is
superior, overall, to that of the CE-SAV porcine bio-
prosthesis with regard to freedom from SVD in MVR
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Table I. Demographics of patient populations
CE-P CE-SAV
Mitral (%) Multiple (%) Combined (%) Mitral (%) Multiple (%) Combined (%)
Gender (female) 59.2 57.8 58.9 61.3 53.5 60.0
Age group (y)
0-40 9.3 6.9 8.7 5.4 4.5 5.3
41-50 6.9 3.9 6.2 8.7 8.0 8.6
51-60 27.3 21.6 26.0 17.1 11.0 16.1
61-70 38.7 42.2 39.5 35.5 32.0 34.9
>70 17.7 25.5 19.5 33.3 44.5 35.1
Valve size (mm)
25 1.8 4.9 2.5 10.4 14.0 11.0
27 36.9 37.3 37.0 34.5 34.5 34.5
29 39.9 39.2 39.8 31.9 34.0 32.2
31 18.3 18.6 18.4 16.1 13.5 15.7
33 3.0 0 2.3 6.7 3.5 6.2
Concomitant CABG 15.8 11.9 14.9 34.6 21.5 32.5
Previous valve 27.7 17.8 25.4 17.3 23.5 18.2
operation
CABG, Coronary artery bypass grafting.
surgery. No controlled studies have compared the sec-
ond-generation CE-P pericardial prostheses with the
second-generation porcine bioprostheses, namely, the
CE-SAV and the Hancock II valves in either aortic
valve replacement or MVR.
The documentation afforded from the literature does
not seem to differentiate these prostheses in the aortic
position after 10 and 12 years of evaluation. The free-
dom from SVD beyond 10 years is incomplete. The
freedom from SVD for aortic valve replacement at 10
years and 12 years with the CE-SAV bioprosthesis was
91% and 83%, respectively, overall, with a mean age
of 65 years.16 In other series with similar mean ages,
the freedom from SVD at 10 years was 92% for the
Hancock II porcine bioprosthesis and ranged from
87% to 100% for the CE-P bioprosthesis.4-12 The
series reported by Neville and colleagues5 revealed a
94% freedom at 12 years with the aortic CE-P bio-
prosthesis, but the mean age was 68 years. Banbury
and coauthors9 reported a freedom from SVD of 82%
at 12 years with the CE-P valve, also in the aortic posi-
tion, in patients with a mean age of 64 years. Poirier
and colleagues11 reported CE-P freedom from SVD of
93% and 80% at 10 and 14 years, respectively. Further
extended reports are required for comparative evalua-
tions.
The current comparative study has been performed
only on prostheses explanted for SVD. The follow-up
from the CE-P centers included SVD diagnosed at
reoperation. The CE-SAV experience at the University
of British Columbia includes an additional 66 cases
that were not included in reoperation for explant for the
study. Of this group, 24 were diagnosed without reop-
eration and 37 were previously diagnosed with stent
dehiscence at reoperation. The stent dehiscence mode
of failure was identified in prostheses implanted
between 1982 and 1986. The stent dehiscence caused
normal-appearing tissue to separate from the origin of
the stent post and the resultant release of 2 leaflets with
mitral regurgitation as the ultimate consequence.13-16
When the prosthesis was introduced in 1982, the tissue
had been prepared with the aortic wall being extensive-
ly trimmed. With the identification of that stent dehis-
cence likely being related to extensive aortic wall trim-
ming, the manufacturer altered the way in which the
tissue was prepared. In 1986, the manufacturer intro-
duced reduced trimming of the aortic wall of large
mitral prostheses, and in 1987 this practice was extend-
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Table II. Results of Cox regression analysis for predictors of SVD diagnosed at explant reoperation for the overall
MVR population
Variable Category Odds ratio CI P value
Model I (age as continuous variable)
Valve type CE-P Baseline
CE-SAV 2.966 1.983-4.434 .0001
Age 0.962 0.953-0.971 .0001
Model II (age as categoric variable)
Valve type CE-P Baseline
CE-SAV 2.891 1.930-4.331 .0001
Age 0-40 Baseline
41-50 0.855 0.551-1.325 .483
51-60 0.598 0.393-0.910 .016
>60 0.320 0.211-0.484 .0001
CI, Confidence interval.
Table III. Actuarial freedom from SVD of overall MVR by age groups
Number (n) Percent freedom at 5 years (n) Percent freedom at 10 years (n)
Age groups (years) CE-P CE-SAV CE-P CE-SAV CE-P CE-SAV
≤40* 38 67 97.1 ± 2.8 (34) 93.9 ± 3.4 (44) 79.7 ± 7.6 (16) 59.5 ± 7.8 (18)
41-50* 109 27 100 (26) 95.5 ± 2.2 (78) 91.1 ± 6.1 (10) 60.7 ± 5.9 (34)
51-60* 108 204 98.8 ± 1.2 (78) 100 (152) 84.3 ± 5.0 (30) 69.4 ± 4.5 (54)
61-70* 171 442 100 (128) 98.4 ± 0.8 (223) 95.2 ± 2.1 (46) 75.2 ± 3.7 (69)
>70 85 444 100 (55) 100 (136) 100 (9) 91.5 ± 3.2 (34)
Numbers at risk at 5 and 10 years are given in parentheses.
*P < .05, CE-P > CE-SAV bioprostheses.
ed to all sizes of mitral and aortic prostheses. Inasmuch
as we believe the problem of early stent dehiscence has
been resolved, the cases of stent dehiscence were not
incorporated in the analysis to provide an appropriate
representation of the current CE-SAV valve perfor-
mance and to have extended follow-up for comparison.
Documentation of the performance of the CE-P
mitral prosthesis has been limited, and the prosthesis
has not been widely implanted. In 1995, Pelletier and
colleagues10 reported on the experience at the Montreal
Heart Institute, where the CE-P valve is the biologic
prosthesis of choice. The freedom from SVD at 10
years was 79% for MVR and 77% for multiple valve
replacement. Poirier and colleagues11 reported further
on this experience, with an 81% freedom from SVD at
10 years. In 1995, Takahara and coauthors17 reported
an 84% freedom from SVD at 9 years. Murakami and
associates,18 reporting in 1996, indicated that the free-
dom from SVD in a patient population with a mean age
of 57 years was 77% at 10 years for MVR. Aupart,19
Carpentier,20 and their colleagues have reported exten-
sively on their experience with the CE-P prosthesis. At
12 years the freedom from SVD was 94% for the pros-
thesis in the mitral position. In their multiple replace-
ment population, the freedom for patients 60 years of
age or younger was 93% at 10 years.24
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Fig 1. Actuarial freedom from SVD for overall MVR in the 61- to 70-year age group.
Fig 2. Actuarial freedom from SVD for overall MVR for the age group 60 years and younger.
The identified reduced performance of the second-
generation CE-SAV mitral prosthesis is certainly of
concern. The difference in the mean ages of the 2 pop-
ulations does not afford an opportunity for an overall
statement of freedom for MVRs. In the overall MVRs,
the actuarial freedom from SVD for CE-P prostheses
was superior to that of CE-SAV prostheses for the age
groups 40 years and younger, 41 to 50 years, 51 to 60
years, and 61 to 70 years. No significant differences
were observed in the age group older than 70 years, but
the trend was impressive: 100% for CE-P bioprostheses
and 92% for CE-SAV bioprostheses at 10 years. The
University of British Columbia experience, document-
ing all SVD cases diagnosed clinically, at autopsy, or at
reoperation, was reported in 1997 for the same age
groupings.25 For MVR the 10-year freedom from SVD
was 70% for the 41- to 50-year age group, 59% for the
51- to 60-year group, and 55% for the 61- to 70-year
group; at 12 years, the freedom from SVD was 87% for
the age group older than 70 years. The freedom from
SVD in the elderly is in keeping with previous reports,
including the extensive report by Burr and colleagues26
from the University of British Columbia. The Hancock
II experience, by David, Armstrong, and Sun,12 has not
been documented by the same age categorization, but
the overall freedom from mitral SVD at 12 years was
82% with a mean age of 65 years.
The actual freedom from SVD for the overall MVRs
was also provided to avoid overestimation of the inci-
dence of SVD.22,23 The actual analysis accounts for the
many patients who died of unrelated causes before the
bioprostheses failed, thus providing a better estimate of
durability of bioprostheses, especially in patients with
reduced expectancy of survival. The observational com-
parison of actuarial and actual freedom from SVD is
important for physicians and surgeons in the decision-
making process. In summary, the actual freedom at 10
years for CE-P versus CE-SAV prostheses for overall
MVR was as follows: for 40 years of age or younger,
82% versus 68%; for 41 to 50 years, 92% versus 70%;
for 51 to 60 years, 90% versus 80%; for 61 to 70 years,
97% versus 88%; and older than 70 years, 100% versus
97%, respectively.
The cause of the increased degree of failure with the
CE-SAV valve is likely contributed to by the prosthesis
design. The CE-SAV mitral prosthesis was designed
with reduction in strut height to minimize protrusion
within the ventricular cavity. The concept of the low-
profile bioprosthesis has been given consideration in
assessing the mode of failure in the long-term of the
low-profile St Jude Medical BioImplant (Liotta)
porcine bioprosthesis (St Jude Medical Inc, St Paul,
Minn).27,28 Valve regurgitation has been identified by
Ius and colleagues28 as the usual mode of failure of the
Liotta prosthesis in the mitral position. These authors
have identified that commissural tearing of the right
coronary cusp was the most common cause of valve
regurgitation and occurred even in the presence of min-
imal calcification. The pathologic findings imply
bulging of the right coronary cusp, which increases the
risk of increased stress at the commissures, accelerat-
ing calcification and tearing. The low profile design of
the CE-SAV mitral prosthesis may also be a contribut-
ing factor to structural failure and requires further
detailed pathologic assessment. The CE-P bioprosthe-
sis, on the other hand, is designed by computer-gener-
ated leaflet sizing according to stent size so that com-
missural stress is minimal. The design of these 2
prostheses is likely the differentiating factor in the dif-
ferences in clinical performance at 10 years.
The actual pathologic mode of failure has been iden-
tified to be dissimilar. The majority of CE-P failures are
from primary dystrophic calcification, whereas for CE-
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Table IV. Actual freedom from SVD for overall MVR by age groups
Number (n) Percent freedom at 5 years (n) Percent freedom at 10 years (n)
Age groups (years) CE-P CE-SAV CE-P CE-SAV CE-P CE-SAV
≤40 38 67 97.4 ± 2.6 (35) 95.0 ± 2.8 (45) 82.2 ± 6.7 (17) 67.9 ± 6.4 (19)
41-50 109 27 100 (27) 96.1 ± 1.9 (79) 92.2 ± 5.3 (11) 69.5 ± 4.8 (35)
51-60 108 204 99.1 ± 0.9 (79) 100 (153) 89.8 ± 3.3 (31) 80.0 ± 3.0 (56)
61-70 171 442 100 (129) 98.9 ± 0.5 (224) 96.8 ± 1.4 (47) 87.6 ± 1.9 (70)
>70 85 444 100 (56) 100 (137) 100 (10) 96.5 ± 1.3 (35)
Numbers at risk at 5 and 10 years are given in parentheses.
Table V. Pathology of SVD for CE-P and CE-SAV bio-
prostheses for MVR
CE-P CE-SAV
Calcification (%) 70.4 16.9
Leaflet tear (%) 18.5 26.6
Calcification/leaflet tear (%) 11.1 56.5
SAV valves the primary cause is the combination of
calcification and leaflet tearing. These findings indicate
that the patients with CE-P SVD will present with
mitral stenosis and those with CE-SAV SVD with
mitral regurgitation. The CE-SAV patient is more likely
to have acute symptoms whereas the CE-P patient may
The Journal of Thoracic and
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Fig 3. Actual freedom from SVD for overall MVR for the 61- to 70-year age group.
Fig 4. Actual freedom from SVD for overall MVR for the age group 60 years of age or younger.
Table VI. Patient survival for overall MVR by age groups
Number (n) Percent freedom at 5 years (n) Percent freedom at 10 years (n)
Age groups (years) CE-P CE-SAV CE-P CE-SAV CE-P CE-SAV
≤40 38 67 94.6 ± 3.7 (34) 86.3 ± 4.4 (45) 86.7 ± 6.4 (16) 74.9 ± 7.2 (18)
41-50 109 27 96.3 ± 3.6 (26) 83.5 ± 3.7 (78) 77.7 ± 9.3 (10) 77.3 ± 4.3 (34)
51-60 108 204 74.8 ± 4.2 (78) 80.7 ± 2.8 (153) 64.2 ± 4.8 (30) 64.1 ± 3.8 (54)
61-70* 171 442 75.4 ± 3.3 (128) 65.1 ± 2.4 (224) 56.8 ± 4.0 (46) 38.0 ± 2.9 (70)
>70 85 444 64.7 ± 5.2 (55) 55.8 ± 2.8 (136) 25.6 ± 5.9 (9) 28.6 ± 3.2 (34)
Numbers at risk at 5 and 10 years are given in parentheses.
*P < .05, CE-P > CE-SAV bioprostheses.
have insidious chronic valvular stenosis. Planned
echocardiographic surveillance of the CE-P prosthesis
will be a greater need than for the CE-SAV prosthesis.
These failure modes could change the clinical perfor-
mance by the 15- and 20-year intervals.
This study concludes that at 10 years the incidence of
SVD is greater for the CE-SAV porcine bioprosthesis
than for the CE-P pericardial bioprosthesis. The pros-
thesis designs are likely the contributing factors to
these differences. Long-term evaluation to 15 and 20
years is a necessity.
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Discussion
Dr Walter Wolfe (Durham, NC). I first would agree that
death is final. This paper cries out for echocardiography,
because echocardiography is going to be the best means of
evaluating failure of these valves.
This paper contains a great deal of information and merits
close study. At Duke, we stopped using tissue valves in the
mitral position for a long time in the 1980s, for a number of
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reasons. The history of these valves remains unsettled, but
they are known to fail. Early on, the recommendation was
that patients receive anticoagulation for 1 month and then 2
months. Did any of these patients receive anticoagulation over
a period of time?
Dr Jamieson. Generally the patients received anticoagu-
lant therapy for approximately 4 to 6 weeks in the various
centers, although there is some variation within the centers. If
the patients remained in sinus rhythm, anticoagulation thera-
py would be discontinued and replaced with antiplatelet ther-
apy. Those who had chronic atrial fibrillation would continue
to receive anticoagulants. Unfortunately, because there were
8 centers, I cannot provide exact figures.
Dr Wolfe. Currently the operation of choice in the mitral
valve is a repair, but perhaps concern over the use of a certain
prosthesis in the mitral position is no longer necessary.
I still believe these valves have several problems. Early on,
after the pericardial valve became available, we initially
inserted it without echocardiographic evaluation. We know
that echocardiography has improved immensely in the past
10 years. We started seeing a gradient across the valve in the
mitral position, which we believed was a problem with stiff-
ness in the leaflets, and it was for that reason that we stopped
using the valve in the mitral position. In the future, as you
monitor these patients, you will need to look for a progressive
gradient in the mitral position.
In this study, stenosis is the principal cause for failure, as
you pointed out. I wonder whether the fixation process or this
stiffness might lead then to this calcification. Another prob-
lem is leaflet tear, and it appears to be more common in the
Carpentier-Edwards porcine valve, although there have been
manufacturing improvements. My concern is that the cardiol-
ogists regard these valves almost as if they were native
valves. In the aortic position they start seeing a gradient
across the valve of 10, 20, or 30 mm Hg in 4 or 5 years, and
they do not send the patient for valve removal. The patient
has structural valve failure but not clinical failure. Later on,
the valve leaks or suddenly tears and the situation is urgent.
Can you comment on the reason these valves failed and when
they had to be removed?
Dr Jamieson. In approximately 60% of these porcine valves,
failure was caused by a combination of calcification and subse-
quent tear. That was not the excessive calcification that we
know occurs in these pericardial valves. The porcine valve fail-
ure is indicated by regurgitation. Only approximately 16% pre-
sented primarily with pure calcification without a tear, which
was the opposite of the situation in the pericardial valves.
Dr Wolfe. In 1994, when we published our series, we had
10 years of survival data on the valves, 57% in the mitral
position, 76% in the aortic, and 95% in the tricuspid position.
In the patients older than 60, we had a 90% 10-year valve sur-
vival. One of the interesting things we observed was that the
larger mitral valves seemed to fail earlier, that is, valve sizes
31 or greater had an earlier failure rate than the smaller
valves. Do you have a comment regarding that in your data?
Dr Jamieson. Valve size was not an independent predica-
tor of failure.
We have 15 years of data with about a 90% valve survival
in the aortic position in patients older than 60. However, in
the mitral position in patients younger than 60, the valve sur-
vival is much less. I favor a mechanical valve in the mitral
position much of the time, even in healthy patients, because
these tissue valves will fail in 10 to 12 years and the patient
will return for a replacement.
Dr Wolfe. What was the explant mortality? Removal of
these valves can be a difficult task.
Dr Jamieson. The explant mortality in the Vancouver series
was 3% in the overall mitral population. I do not have the full
data from all the centers to tell you the complete figure.
Dr Wolfe. I certainly agree that the principal mode of fail-
ure will be stenosis with the pericardial valve, and that will be
better tolerated by the patient. Consequently, you are going to
encounter what I would call structural valve failure earlier in
the follow-up period, before you explant. Therefore, serial
echocardiographic data in the follow-up of these patients is
going to be extremely important.
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